anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The cardiovascular safety from azithromycin in the treatment of several infectious diseases has been challenged. In this prespecified pooled analysis of 2 multicenter randomized clinical trials, we aimed to assess whether the use of azithromycin might lead to corrected QT (QTc) interval prolongation or clinically relevant ventricular arrhythmias. In the COALITION COVID Brazil I trial, 667 patients admitted with moderate COVID-19 were randomly allocated to hydroxychloroquine, hydroxychloroquine plus azithromycin, or standard of care. In the COALITION COVID Brazil II trial, 447 patients with severe COVID-19 were randomly allocated to hydroxychloroquine alone versus hydroxychloroquine plus azithromycin. The principal end point for the present analysis was the composite of death, resuscitated cardiac arrest, or ventricular arrhythmias. The addition of azithromycin to hydroxychloroquine did not result in any prolongation of the QTc interval (425.8 ± 3.6 ms vs 427.9 ± 3.9 ms, respectively, mean difference -2.1 ms, 95% confidence interval -12.5 to 8.4 ms, p = 0.70). The combination of azithromycin plus hydroxychloroquine compared with hydroxychloroquine alone did not result in increased risk of the primary end point (proportion of patients with events at 15 days 17.2% vs 16.0%, respectively, hazard ratio 1.08, 95% confidence interval 0.78 to 1.49, p = 0.65). In conclusion, in patients hospitalized with COVID-19 already receiving standard-of-care management (including hydroxychloroquine), the addition of azithromycin did not result in the prolongation of the QTc interval or increase in cardiovascular adverse events. Because azithromycin is among the most commonly prescribed antimicrobial agents, our results may inform clinical practice. Clinical Trial Registration: NCT04322123, NCT04321278.
To provide dried Polygonum tinctorium Lour. leaves containing enzyme in the state of high enzymatic activity, to provide methods for producing the dried Polygonum tinctorium Lour. leaves efficiently, to provide dried Polygonum tinctorium Lour. leaves suitable for hair dyeing, coloring, as a precipitation or a pigment, and to provide a Polygonum tinctorium Lour. precipitation or a Polygonum tinctorium Lour. pigment for medicines, cosmetics, soap, coloring, or functional foods.SOLUTION: Provided is a method in which the amount of functional materials in dried Polygonum tinctorium Lour. leaves is held high or increased, as compared with normal low-temperature dried or microwave reduced pressure dried Polygonum tinctorium Lour. leaves, by controlling enzymes in raw Polygonum tinctorium Lour. leaves by microwave irradiation, in a microwave drying or aging-drying method of Polygonum tinctorium Lour. leaves. By the control of enzymatic activity in raw Polygonum tinctorium Lour. leaves, the enzymatic activity in raw Polygonum tinctorium Lour. leaves is controlled, or activated, and promoted.SELECTED DRAWING: None
Embodiments of the present inventions comprise composites of bone particles and polyurethane(s), as well as methods of making such composite and uses thereof. Certain embodiments further comprise a growth factor that can be provided in powder form. Growth factors may be bone morphogenic proteins, such as rhBMP-2. A porous composite comprises a plurality of bone particles, polyurethanes with which the bone particles are combined, and at least one growth factor. A composition may be moldable and/or injectable. After implantation or injection, a composition may be set to form a porous composite that provides mechanical strength and supports the in-growth of cells. Inventive composites have the advantage of being able to fill irregularly shape implantation site while at the same time being settable to provide the mechanical strength for most orthopedic applications.
This group will receive comprehensive assessments every 9 months for the 18-month period of enrollment, for a total of 3 assessments. They will not be randomized to receive supplemental teletherapy (intervention) and usual care.
Fecal Microbiome Transplants: Patients will undergo pretreatment with Amoxicillin/Clavulinate (or matched placebo) for 5 days followed by a bowel cleanse with PEGLYTE. Patients will undergo allogeneic or autologous fecal transplants. Patients will be dosed with FMT oral capsules approximately 48 hours after antibiotic treatment has stopped. Following the FMT capsule treatment on day 1, patients will be administered a repeat oral capsule or placebo dose at 3 weeks. Oral omeprazole or omeprazole placebo will be given 1 hour prior to the baseline and 3 week dose. This will be done to ensure full engraftment of the transplant.

Participants will be seen at baseline, 3 weeks, 6 weeks, 3 months, 6 months and 12 months. A series of neurological tests will be performed for safety measures. In addition to this, MRIs will be completed at baseline, 6 weeks and 12 months. Blood, urine and stool samples will also be collected for data analysis and safety measures.
The annual number of live births in Türkiye is 1,112,859 in 2020 and the estimated incidence of developmental dysplasia of the hip (DDH) is between 5 and 15 per 1000 live births. The implementation of the National DDH Early Diagnosis and Treatment Program by the Türkiye Republic of the Ministry of Health in 2010 significantly reduced the number of patients with DDH diagnosed more than 6 months later. If not appropriately treated, DDH can cause a decrease in the number of healthy life years, and workforce losses, which consequently burdens the social security system and government budget. The vast majority of clinical trials comprise risk factors associated with complications after treatment of DDH. Moreover, studies involving functional assessments are generally focused on adult DDH patients with surgical indications. To the best of the investigators' knowledge, mid-term patient-reported and performance-based functionality has not been examined in conservatively treated patients. In addition, it is not known whether the diagnosis of unilateral and bilateral DDH in these patients will make a difference in Daily activities which require bilateral functionality of the lower limbs. Therefore, in this study, the investigators examined and compared the mid-term patient-reported and performance-based functional outcomes in patients with unilateral and bilateral DDH treated with a hip abduction brace. This study provides new data on mid-term functionality in children with unilateral and bilateral DDH. It can guide determining the lower extremity functional levels of school-age children with DDH, regular follow-up, early diagnosis, and treatment planning for problems.

The vast majority of clinical trials comprise risk factors associated with complications after treatment of DDH. Moreover, studies involving functional assessments are generally focused on adult DDH patients with surgical indications. To the best of the investigators' knowledge, mid-term patient-reported and performance-based functionality has not been examined in conservatively treated patients. In addition, it is not known whether the diagnosis of unilateral and bilateral DDH in these patients will make a difference in activities such as jumping rope, double-leg jumping, walking, and dynamic balance, which require bilateral functionality of the lower limbs. Therefore, the aim of this study is to examine and compare the mid-term patient-reported and performance-based functional outcomes in patients with unilateral and bilateral DDH treated with a hip abduction brace.
Subjects will be maintained on oral phendimetrazine (up to 210 mg/day) administered twice daily for approximately two weeks. Cocaine will be administered acutely during placebo maintenance. Placebo will be administered acutely during placebo maintenance.
PROBLEM TO BE SOLVED: To obtain the subject cosmetic excellent in preservability and stability with the lapse of time, by including, as active ingredient, an extract from Aralia cordata Thunb., a plant belonging to the genus Araliaceae. SOLUTION: This cosmetic is obtained by including, as active ingredient, pref. 0.5-50 wt.% of an extract from Aralia cordata Thunb., a plant belonging to the genus Araliaceae, ordinarily used as a food. The extract is prepared, for example, by the following method: the leaves and stems of the plant on the ground raised to a height of about 1.5 m are cut to 5 cm or so, dried, and then put to seepage with about 10 wt. times of alcohol and subjected to reflux extraction at 70-90 deg.C until the remaining alcohol level comes at 5 wt.% or so, and the resulting liquid extract is diluted with purified water by a factor of about 10. This cosmetic may be appropriately formulated, besides the above extract, with ingredients used conventionally in cosmetics.
This study provides three real scenarios regarding dilemma between ethics and law when patient's surrogate may not represent patient's best interest：1. Parents ask physician resect their mentally handicapped daughter's uterus. 2. A son refuse physician's suggestion of surgical treatment for his mother, instead, wishes donating his mother's kidney to his son. 3. A mother decides to give up treatment for her son's head injury because of his rebel behavior before.

T-test, ANOVA and Logistic Regression will be used to analyze in this study.
An inverted aerosol dispensing device (10A) is disclosed comprising an aerosol container (20A) extending between a top portion (21A) and a bottom portion (32A) for containing an aerosol product (14) and an aerosol propellant (16) therein. An aerosol valve (80A) is located at the bottom portion of the aerosol container. The aerosol valve has a valve stem (82A) for displacing the aerosol valve from a biased closed position to an open position to discharge the aerosol product from the valve stem. An undercap (30A) is secured to the bottom portion of the aerosol container for supporting the aerosol container on a supporting surface. An actuator (50A) is movably mounted relative to the undercap for moving the valve stem upon displacement of the actuator for discharging the aerosol product from the valve stem in a generally downwardly direction through the undercap. The invention is particularly useful in the dispensing of viscous aerosol products.
In an aspect, a system for a cloud-based user physiology detection software and patient monitoring system. A system includes a wearable device. A wearable device includes a sensor. A sensor is configured to receive physiological data from a user. A system includes a patient monitor configured to monitor a vital sign of a user. A system includes a therapeutic delivery device configured to administer a therapeutic remedy to a user. A system includes a computing device configured to modify a therapeutic remedy of a therapeutic delivery device as a function of physiological data. A method of providing a therapeutic remedy using a cloud-based detection software is also disclosed.
The invention discloses freeze-drying, non freeze-drying hydroquinone monocarbonylate nano-emulsions for beauty treatment and a process for preparation. The freeze-drying nano-emulsions contain the following materials by weight proportion: hydroquinone monocarbonylate 0.5-4 parts, vitamin E 0.2-2.0 parts, isopropyl myristate 8-18 parts, octanoic acid capric acid triacetate 0.1-1.0 parts, octanoic acid capric acid glycedol 32-40 parts, polyglycerol fatty acid esters 10-14 parts, double distilled water 35-45 parts, manna sugar 15-25 parts, aminoacetic acid1-6 parts. The non freeze-drying nano-emulsions contain the following materials by weight proportion: monocarbonylate 0.5-4 parts, vitamin E 0.2-2.0 parts, isopropyl myristate 8-18 parts, octanoic acid capric acid triacetate 0.1-1.0 parts, octanoic acid capric acid glycedol 32-40 parts, polyglycerol fatty acid esters 10-14 parts, double distilled water 35-45 parts. The invention has the advantages of simple preparation method, easy practical operation and industrialization, stable quality of products, prolonged storage time, and effective and quick preparation. The whole process for preparion can be finished in less than 30 minutes. No special apparatus is needed. Great progress has been made in saving energy and materials, and reducing the environmental contamination.
Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose until blood pressure has stabilized (See WARNINGS, and DOSAGE AND ADMINISTRATION). When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. Studies with ACE inhibitors in combination with diuretics indicate that the dose of the ACE inhibitor can be reduced when it is given with a diuretic. (See DOSAGE AND ADMINISTRATION).
In this study, the standard control, control group receipts schroth exercise therapy, while trial group receives Schroth exercise therapy and laser therapy. The design of the individual Schroth exercise is carried out according to the c urve patterns of the Schroth classification. The Schroth classification criteria includes four curve patterns that are determined with reference to the location of the curves, the importance of lumbar and thoracic prominences, and the effect of the scoliosis on the pelvis. Laser therapy was performed w ith a dual wavelength, high power IR laser (Multiwave Locked System (MLS®) laser, Mphi, ASA srl, Vicenza, Italy) and the laser acupuncture points include DU2, GB30, DU9, SP6, LR8, DU6, DU4, DU12. Laser puncture acupuncture points had been identified according to Traditional Chinese Medicine (TCM) and treated with handpiece optical group following the detailed treatment parameters: 900Hz, FPW mode, 60 s per point, 29.12J, spot size 3 cm2, energy density 27J/cm2. All treatments are performed five times in a week for 4 consecutive weeks.
This condition will contain no active elements beyond its nonspecific components, and no theoretical basis to support an effect on CRDs. The attention-control group will also involve 4 in-home visits and 4 brief telephone education sessions. The attention control group will receive printed educational and training materials from the Alzheimer's Association and the NIH on home modification, health promotion, talking to your doctor, and advanced care planning that coincide with session content.
PURPOSE: Language sample analysis (LSA) is a commonly recommended method of assessment for bilingual children. This systematic review and meta-analysis provides a comprehensive overview of the literature on the use of LSA to differentiate between developmental language disorder (DLD) and typical language (TL) in bilingual children.
METHOD: We conducted a search of several large electronic databases along with forward and backward searches and applied abstract and full-text screening procedures to identify all relevant studies. We then estimated standardized mean differences, representing the ability of LSA to differentiate between DLD and TL, using multilevel model and subgroup and moderator analyses to identify characteristics of LSA that may be associated with differences in effect size magnitude. We conducted assessments of publication bias and risk of bias by examining quality indicators for each study.
RESULTS: The search yielded 35 articles that met the inclusion criteria. Participants ranged in age from 2;0 (years;months) to 11;9, with over 40 languages represented. Across studies, the pooled standardized mean difference indicated that children with DLD performed 0.78 SD lower on LSA measures than those with TL. Measures of morphosyntactic accuracy exhibited the largest pooled effect size. Elicitation method, language of task, and age were not associated with differences in effect size.
DISCUSSION: Results of this study provide evidence of the clinical utility of LSA in differentiating between DLD and TL in bilingual children. Further research is needed to examine classification accuracy as well as task characteristics that may improve its diagnostic utility.
Subjects who are randomized to telerehabilitation will be provided access to telemedicine visits with a physical therapist. Patients will have one in-person physical therapy visit before starting telerehabilitation, and another in-person visit at 3 months to assess progress. Telerehabilitation visits will be performed via secure usage of the electronic medical record (EMR). To ensure uniformity, and to allow for appropriate access to telehealth services, all telehealth visits will be carried out through the study institution's Department of Physical Therapy. It is expected most patients will complete formal physical therapy by 6 months postoperative measured by the time at which patient's regain functional range of motion or patients are satisfied with their results. Shoulder range of motion will be measured with a goniometer preoperatively, as well as 3,6, 12, and 24 months postoperatively at their regularly scheduled clinic visit.
The present invention provides branched water-soluble polymers that allow tw o or more water-soluble polymers to be conjugated to another species. The branched polymers provide access to therapeutic agents that are conjugated a t a single site to two or more water-soluble polymers. The branched polymers a re based upon branch points that are simple branched alkyl structures, reactive side-chain amino acids and small peptides of reactive side-chain amino acids , and saccharides. Also provided is a method for preparing mono-disperse poly(ethylene glycol) of a well-defined and determinable molecular weight, a nd a method for the rational end-functionalization of poly(ethylene glycol). Conjugates of the branched water-soluble polymers with diverse species, e.g. , peptides, lipids, glycolipids and small molecules are also provided.
NEW MATERIAL:The compound of formulaI(one of R1-R3 is H and the others are CH3; X is group of formula II or formula III). USE:It has antibacterial, antimycotic and antiprotozoal activities and is expected to have antitumor activity. PROCESS:The compound of formulaIcan be prepared by contacting the compound of formula IV (i.e. macbecinIor macbecin II) with the cultured product (or its treated product) of microorganisms belonging to Streptomyces genus or Nocardia genus and capable of converting the 17-, 18- or 21-methoxy group of said compound to hydroxyl group, at 6-9pH and 24-40 deg.C for 16-72hr. The microorganism is, e.g. Streptomyces platensis IFO 12901 (ATCC 23948=13865), Nocardia mediterranei ATCC 13685 (IFO 13415), etc.
INTRODUCTION: Follicular helper T cells are essential for helping in the maturation of B cells and the production of neutralizing antibodies (NAbs) during primary viral infections. However, their role during recall responses is unclear. Here, we used hepatitis C virus (HCV) reinfection in humans as a model to study the recall collaborative interaction between circulating CD4 T follicular helper cells (cTfh) and memory B cells (MBCs) leading to the generation of NAbs.
METHODS: We evaluated this interaction longitudinally in subjects who have spontaneously resolved primary HCV infection during a subsequent reinfection episode that resulted in either another spontaneous resolution (SR/SR, n = 14) or chronic infection (SR/CI, n = 8).
RESULTS: Both groups exhibited virus-specific memory T cells that expanded upon reinfection. However, early expansion of activated cTfh (CD4+CXCR5+PD-1+ICOS+FoxP3-) occurred in SR/SR only. The frequency of activated cTfh negatively correlated with time post-infection. Concomitantly, NAbs and HCV-specific MBCs (CD19+CD27+IgM-E2-Tet+) peaked during the early acute phase in SR/SR but not in SR/CI. Finally, the frequency of the activated cTfh1 (CXCR3+CCR6-) subset correlated with the neutralization breadth and potency of NAbs.
CONCLUSION: These results underscore a key role for early activation of cTfh1 cells in helping antigen-specific B cells to produce NAbs that mediate the clearance of HCV reinfection.
PURPOSE: To obtain a new antitumor substance epolactaene produced by a new mold belonging to the genus Penicillium and useful as an antitumor agent and a nerve differentiation inducing agent. CONSTITUTION: This epolactane is expressed by the formula. The compound is produced preferably by using an epolactane-producing strain belonging to the genus Penicillium such as Penicillium sp. BM1689-P and culturing the strain on a Czapek agar medium, Czapek yeast extract agar medium or malt extract agar medium at 10-38 deg.C (especially 32 deg.C). The compound can be administered by oral administration as well as parenteral administration. In the case of nasal administration, the daily dose of the active component for adult is 1-100mg/kg (preferably 2-10mg/kg) in one dose or several divided doses.
BACKGROUND: Chronic Energy Deficiency (CED) is a condition in which the body is underweight or thin and the body has insufficient reserves of energy intake, this condition occurs due to a lack of nutrients. A person's condition can be said to be CED if the Mid-Upper Arm Circumference (MUAC) is low or < 23,5 cm. Women of Reproductive Age (WRA) who experience CED will have an impact on pregnancy. Based on the 2017 World Health Organization (WHO) the percentage of CED in pregnancy globally is 35-75% and deaths in developing countries related to CED are 40%.
METHODS: Research design Descriptive analytic cross-sectional approach. The population WRA with a population of 7,183 the sample being 143 WRA. The analysis is univariate, bivariate (Chi-square), and multivariate (Regression Logistic).
RESULTS: Found that the determinants of CED were factors affecting CED for WRA in the Kandang Health Center in Bengkulu City in 2023 are age (p-value = 0.018; ORa95% CI=2,495: 1.171-5.317), energy intake (p-value = 0.013; ORa95% CI = 2.990: 1.256-7.117), and the interaction of protein intake by several family members (p-value = 0.03; ORa 95%CI = 21.327: 1.343-338.671). The dominant factor is the interaction between protein intake and the number of family members. WRA with large families when protein intake is not enough risk 21 times to experience chronic lack of energy compared to adequate protein intake.
CONCLUSIONS: Health workers need to make promotive and preventive efforts that can be done through community empowerment through health education about nutritional intake and family planning, so WRA understands about prevention of Chronic Energy Deficiency.
There will be four groups. Group 1a and Group 1b will provide semi-intensive PK data and safety monitoring to allow for comparison of twice-daily dolutegravir exposures together with HP vs. when DTG is given alone. Group 2a and Group 2b will provide semi-intensive PK data and safety monitoring for either twice-daily or once-daily dolutegravir together with HIV vs when DTG is given alone. All groups will provide safety and tolerability data, HIV virologic outcome data, and information about dolutegravir and rifapentine PK.